Profiling the Current Companion Diagnostics Landscape

Profiling the Current Companion Diagnostics Landscape

With the approval of Qiagen’s therascreen KRAS RGQ PCR Kit for use with the Amgen drug Vectibix, the number of applications for non-LDT, marketed companion diagnostics (CDx) products in the United States has reached 20. The companion in vitro diagnostics market is entering a new phase with over half of all FDA approvals in the previous four years and a burgeoning pipeline. Close collaboration has been key to recent simultaneous pharmaceutical-CDx FDA approvals, and partnerships between IVD compa...

  • by bcarlson@marketresearch.com
  • May 28 2014
  • U.S. IVD


For Roche, Brave Face on Reimbursement Cuts

For Roche, Brave Face on Reimbursement Cuts

Roche won’t cut prices despite reimbursement reductions, according to a recent Reuters story. This isn’t surprising according to Kalorama. We think that there’s a ’have to buy’ element to the diagnostics industry that will sustain markets. We cover the United States in vitro diagnostic industry in our new report.

"Labs will still have to keep buying and some companies will just ride out the storm," said Kalorama’s Emil Salazar, author of our US IVD report. "At most the US is 25% of Roche’s dia...

  • by bcarlson@marketresearch.com
  • May 21 2014
  • EHR
  • EMR


Smaller EMR Firms Gaining on the IT Giants

Smaller EMR Firms Gaining on the IT Giants

EMR was once dominated by the same names that dominated healthcare IT including hospital computing and billing systems. Those firms, McKesson and Cerner still rate high. But smaller companies that can focus on EMR are taking share from healthcare IT giants that offer all-in-one solutions, according to our latest report. Epic Systems is an example, and has moved from fourth to third in Kalorama’s market share estimates.

The company has systems in the Cleveland Clinic, Mount Sinai New York, Univ...

  • by bcarlson@marketresearch.com
  • May 19 2014


Pfizer-Astra Zeneca: No Surprise

Pfizer-Astra Zeneca: No Surprise

At this point, Pfizer’s bid for Astra Zeneca appears to be over , slowing at least a spree of consolidation in the pharmaceutical industry. This is no surprise, according to our pharmaceutical analyst Melissa Elder. Elder, the author of our Top 25 Pharmaceutical Companies report, felt Pfizer was downplaying the value of Astra Zeneca:

Astra is not in as bad of shape as Pfizer is claiming. Astra has a decent pipeline and several promising developments. The company is focusing its efforts on the ...


Playing with Food - Testing Companies and Reference Labs Upgrade Diagnostics to Meet Demand

Playing with Food - Testing Companies and Reference Labs Upgrade Diagnostics to Meet Demand

“Oh my, what’s in this?” is often a complimentary inquiry after sampling from one’s plate, but has become a loaded - and lucrative - question further up the supply chain. Industry food safety testing is not only intensifying - with the implementation of new regulation in North America and abroad - but also growing more complex in response to compounding threats to food safety and brand stability. Labs are racing to improve their advanced testing capabilities and address consumer concerns relatin...

  • by bcarlson@marketresearch.com
  • May 13 2014


Bayer Merck OTC Transaction: "A Good Deal for Both"

Bayer Merck OTC Transaction: "A Good Deal for Both"

Consolidation in the pharma industry continues as Merck & Co. sold its over-the-counter products division, for which Bayer AG agreed to pay $14.2 billion. Our analyst Melissa Elder, author of Kalorama Information’s Top 25 Pharmaceuticals Report weighs in.

"On the Bayer-Merck OTC transaction, I believe its a good move for both. Bayer is a leader in the OTC market and this will continue to strengthen the company’s position in the segment. Bayer generates nearly 20% of its sales from consumer hea...

  • by esalazar@marketresearch.com
  • May 9 2014
  • hematology


Sysmex Continues Its Push into the U.S. Hematology Market

Sysmex Continues Its Push into the U.S. Hematology Market

Line item growth of 40% from a company heavily involved in the U.S. hematology market is a startling figure - and precisely what Sysmex Corporation accomplished in the 2013 calendar year. Sysmex hematology sales to the Americas increased from approximately 23.5 billion yen in the 2012 calendar year to 33.0 billion yen in 2013. The significant growth was attributed to several factors :

In the United States, in addition to rising instrument sales, an increase in the installed instrument base led...

  • by bcarlson@marketresearch.com
  • May 6 2014
  • vaccine
  • flu


Vaccine Revenues Near 24 Billion

Vaccine Revenues Near 24 Billion

In 2013, the world market for preventive vaccines totaled $23.9 billion, up from $22.8 billion in 2012 as sales in all segments expanded, according to our latest report. Among some the growth leaders was influenza vaccines, where greater awareness, new products and overstock recovery lead to 3.1 billion in revenues, up from 2.8 billion in 2012.

The influenza increase is significant according to Kalorama because there had been a large decrease in the influenza vaccine market in 2011. Vaccines s...


Gov’t Demonstrates Willingness to Use Surgical Touch in Controlling Physician Office Ancillary Service Spending

Gov’t Demonstrates Willingness to Use Surgical Touch in Controlling Physician Office Ancillary Service Spending

The administration’s 2015 federal budget, never a reliable model for the eventually passed budget, still establishes a favorable precedent for physician office laboratory (POL) testing: distinguishing between anatomic pathology services and the remaining bulk of office lab tests reimbursed under Medicare Part B. As discussed in previous posts of this blog , rate cuts to fee schedules have hit clinical lab testing hard with independent and hospital labs struggling to retain testing profitability ...